logo of US biotech company Novavax ... earlier this year but now makes up less than 1% of cases. Both Pfizer and Moderna’s shots target the KP.2 COVID-19 variant—JN.1 is the parent variant ...

A roundup of the newest places to go and exhibitions to visit during the upcoming fashion week, running from Tuesday to ...

RBC Capital analyst Luca Issi maintained a Hold rating on Moderna (MRNA – Research Report) today and set a price target of $75.00. The ...

SPIKEVAX® is the first updated COVID-19 vaccine authorized in Canada for 2024-2025, offering a timely solution to help protect Canadians ...

Shares of Moderna Inc. MRNA slipped 3.43% to $65.69 Friday, on what proved to be an all-around mixed trading session for the ...

An experimental Moderna mRNA vaccine for mpox has demonstrated greater effectiveness than current shots in reducing disease ...

Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending and pushed back its time frame for breaking even. The company also ...

Shares of Moderna Inc. MRNA slipped 2.63% to $68.02 Thursday, on what proved to be an all-around favorable trading session ...

The billionaire entrepreneur and CEO of IT services company World Wide Technology remains bullish about the future of AI.

Moderna’s shares climbed in the first half of the year, as it scored victories with a product approval and solid clinical trial results. This week the biotech surprised investors with some ...

UCG / Contributor / Getty Images Moderna shares surged Tuesday after Canadian regulators approved the biotech firm’s updated COVID-19 vaccine. Moderna's Spikevax KP.2 targets the KP.2 variant of ...

Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending and pushed back its time frame for breaking even. The company also forecast a ...